NOVIOCELL BV

Their core work

Noviocell is a Dutch biotech SME that develops synthetic biomimetic hydrogels — engineered materials that mimic the mechanical and biochemical properties of living tissue — for cell culture and biological research applications. Their flagship product, Novio-PlainGel, is a reversible thermosensitive hydrogel designed as a synthetic alternative to animal-derived extracellular matrix materials. Beyond product development, they contribute to fundamental research on how mechanical forces regulate cell behavior, studying proteins like integrins and cadherins that cells use to sense and respond to their physical environment. Their work bridges commercial biomaterials and academic mechanobiology, with applications in cancer research and drug discovery.

What they specialise in

How they've shifted over time

Noviocell entered H2020 in 2016 with a narrow commercial focus — validating market feasibility for their Novio-PlainGel hydrogel product through an SME Instrument Phase 1 grant. By 2017, their trajectory shifted toward fundamental science: joining MECHANO-CONTROL as a research partner introduced them to the full mechanobiology toolkit — traction force microscopy, single-molecule techniques, AFM, photo-activation, and multi-scale modelling. The most likely interpretation is that their hydrogel technology became a research tool within the mechanobiology community, pulling the company deeper into academic collaboration.

Noviocell appears to be evolving from a pure biomaterials supplier into a research-grade platform provider for mechanobiology studies, with cancer applications as the most likely near-term commercial direction.

How they like to work

Noviocell takes on both lead and partner roles — coordinating a small Phase 1 feasibility project independently while joining a much larger RIA consortium as a specialist contributor. Their network is small (6 partners, 4 countries), which is typical for an SME that joins consortia where its product or technology fills a specific niche. This suggests they work best as a focused supplier of biomaterial tools and substrates rather than as a broad research coordinator.

Noviocell has collaborated with 6 unique partners across 4 countries, a compact network consistent with targeted consortium participation rather than broad networking. Their European reach is real but modest — they have not yet built the dense multi-country web typical of more established research SMEs.

What sets them apart

Noviocell occupies a rare niche: a commercial SME with a proprietary synthetic hydrogel product that is simultaneously a validated research tool in mechanobiology. Most hydrogel suppliers are either pure materials companies with no research depth, or academic spinoffs with no commercial product — Noviocell sits at the intersection. For consortia studying the physical mechanics of cancer, wound healing, or tissue engineering, they offer both the material substrate and domain expertise in how cells interact with it mechanically.

Highlights from their portfolio

• MECHANO-CONTROL
  A five-year RIA project (2017-2022) on mechanical control of biological function where Noviocell's hydrogel technology met cutting-edge single-molecule and traction force microscopy techniques — their largest project by far at €455K EC funding.
• OPTIMIsE
  As coordinator of this SME Instrument Phase 1 grant, Noviocell demonstrated enough commercial potential in Novio-PlainGel to secure EU validation for their product-to-market strategy.